BioSpace News Archive

VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020 after the market close on Wednesday, May 6, 2020.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In Vitro Diagnostics Directive (IVDD 98/79/EC) and has CE marked (Conformité Européene) its SARS-CoV-2 (COVID-19) antibody microarray.

Trax Management Services Inc. announced today the introduction of the PhoenixDx 2019-nCoV to North America, a COVID-19 test kit that recently received an Emergency Use Authorization from the FDA.

Suneva® Medical, Inc., is proud to announce an exciting new partnership that will further its leadership position in regenerative aesthetics.

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company, today announced that it has updated the structure, key dates and pricing terms for its previously-announced rights offering.

XBiotech Inc. (NASDAQ: XBIT) announced today that human immune donors have now been identified that can support the Company’s development of a True Human™ antibody therapy for COVID-19

HealthpointCapital, the leading private equity firm focused exclusively on musculoskeletal healthcare, today announced the acquisition of a majority stake in IlluminOss Medical, Inc. (“IlluminOss” or the “Company”).

Lupus is a more pervasive and severe disease than many realize, as a number of its symptoms can be invisible.

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today that the company has completed subject enrollment in its ongoing Phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”)

Robust Angel Investor-led Series A expected to fully fund Phase 1/2 clinical study for lead surgical nerve-targeting candidate